Treatment of metastatic melanoma: An overview

ONCOLOGY

Volumn 23, Issue 6, 2009, Pages 488-496

  Bhatia, Shailender ^a   Tykodi, Scott S ^a   Thompson, John A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; ELESCLOMOL; FOTEMUSTINE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LOMUSTINE; NITROSOUREA; OBLIMERSEN; PACLITAXEL; PEGINTERFERON ALPHA2B; PLATINUM DERIVATIVE; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; TICILIMUMAB; UNINDEXED DRUG; VACCINE; VINBLASTINE; VINDESINE;

ADJUVANT THERAPY; ADOPTIVE CELL THERAPY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL SEPSIS; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAPILLARY PERMEABILITY; CELL THERAPY; CHILL; CLINICAL TRIAL; COGNITIVE DEFECT; DELIRIUM; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; FATIGUE; FEVER; HEART ARRHYTHMIA; HUMAN; IMMUNOTHERAPY; INDUCED HYPOTENSION; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; OLIGURIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION; VOLUME OVERLOAD; VOMITING;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 67650491811     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001. (Pubitemid 32786276)
3. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995.
4. Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103-1111, 1998. (Pubitemid 28108747)
5. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998. (Pubitemid 28417410)
6. Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000. (Pubitemid 30846224)
7. Schmidt H, Suciu S, Punt CJ, et al: Pre-treatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25:1562-1569, 2007. (Pubitemid 46733083)
8. Wong JH, Skinner KA, Kim KA, et al: The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 113:389-394, 1993. (Pubitemid 23111532)
9. Fletcher WS, Pommier RF, Lum S, et al: Surgical treatment of metastatic melanoma. Am J Surg 175:413-417, 1998.
10. Lui P, Cashin R, Machado M, et al: Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treat Rev 33:665-680, 2007. (Pubitemid 350082665)
11. Hill GJ 2nd, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53:1299-1305, 1984.
12. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000. (Pubitemid 30036349)
13. Patel P, Suciu S, Mortier L, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: Final results of the randomised phase III study EORTC 18032 (abstract LBA8). Stockholm, 33rd European Society of Medical Oncology (ESMO) Congress, 2008.
14. Quirt I, Verma S, Petrella T, et al: Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 12:1114-1123, 2007. (Pubitemid 350007023)
15. Chiarion-Sileni V, Guida M, Ridolfi R, et al: Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study (abstract 20014). J Clin Oncol 26(15S):723s, 2008.
16. Quagliana JM, Stephens RL, Baker LH, et al: Vindesine in patients with metastatic malignant melanoma: A Southwest Oncology Group study. J Clin Oncol 2:316-319, 1984. (Pubitemid 14106999)
17. Wiernik PH, Einzig AI: Taxol in malignant melanoma. J Natl Cancer Inst Monogr (15):185-187, 1993.
18. Nathan FE, Berd D, Sato T, et al: Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer 88:79-87, 2000. (Pubitemid 30027682)
19. Rao RD, Holtan SG, Ingle JN, et al: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106:375-382, 2006. (Pubitemid 43100447)
20. Hersh EM, O'Day S, Gonzalez R, et al: Multicenter phase II study of ABI-007 (Abraxane) in previously treated and chemotherapy naïve patients with metastatic malignant melanoma (MMM) (abstract 27). Proceedings of the 23rd Annual Chemotherapy Foundation Symposium, New York, 2005.
21. Glover D, Glick JH, Weiler C, et al: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5:574-578, 1987. (Pubitemid 17062494)
22. Evans LM, Casper ES, Rosenbluth R: Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 71:171-172, 1987. (Pubitemid 17030148)
23. Khayat D, Giroux B, Berille J, et al: Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 12:414-420, 1994. (Pubitemid 24261299)
24. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22:1118-1125, 2004. (Pubitemid 41095046)
25. Del Prete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984. (Pubitemid 15222028)
26. Lattanzi SC, Tosteson T, Chertoff J, et al: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5:365-369, 1995.
27. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999. (Pubitemid 29415231)
28. Legha SS, Ring S, Papadopoulos N, et al: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64:2024-2029, 1989. (Pubitemid 19280399)
29. Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7:827-835, 1996. (Pubitemid 26345874)
30. Hodi FS, Soiffer RJ, Clark J, et al: Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25:283-286, 2002. (Pubitemid 34602552)
31. Agarwala SS, Keilholz U, Hogg D, et al: Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (abstract 8510). J Clin Oncol 25(18S):474s, 2007.
32. Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6(suppl 1): S11-S14, 2000. (Pubitemid 30117631)
33. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999.
34. Smith FO, Downey SG, Klapper JA, et al: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14:5610-5618, 2008.
35. Creagan ET, Ahmann DL, Frytak S, et al: Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: Results in 96 patients. Cancer Treat Rep 70:619-624, 1986. (Pubitemid 16036557)
36. Dummer R, Garbe C, Thompson JA, et al: Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 24:1188-1194, 2006. (Pubitemid 46638817)
37. Thomson DB, Adena M, McLeod GR, et al: Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial. Melanoma Res 3:133-138, 1993. (Pubitemid 23156589)
38. Bajetta E, Di Leo A, Zampino MG, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-811, 1994. (Pubitemid 24110922)
39. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998. (Pubitemid 28234718)
40. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999. (Pubitemid 29109330)
41. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002. (Pubitemid 34408794)
42. Ridolfi R, Chiarion-Sileni V, Guida M, et al: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20:1600-1607, 2002. (Pubitemid 34260541)
43. Kaufmann R, Spieth K, Leiter U, et al: Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23:9001-9007, 2005. (Pubitemid 46211484)
44. Bajetta E, Del Vecchio M, Nova P, et al: Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17:571-577, 2006.
45. Atkins MB, Hsu J, Lee S, et al: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748-5754, 2008.
46. Ives NJ, Stowe RL, Lorigan P, et al: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25:5426-5434, 2007. (Pubitemid 350232219)
47. Tarhini AA, Kirkwood JM, Gooding WE, et al: Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 25:3802-3807, 2007. (Pubitemid 47477253)
48. Miller AJ, Mihm MC Jr: Melanoma. N Engl J Med 355:51-65, 2006.
49. Ribas A, Hauschild A, Kefford R, et al: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma (abstract LBA9011). J Clin Oncol 26(15S):485s, 2008.
50. Downey SG, Klapper JA, Smith FO, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13(22 pt 1):6681-6688, 2007. (Pubitemid 350206804)
51. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006. (Pubitemid 46630937)
52. McDermott DF, Sosman JA, Gonzalez R, et al: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol 26:2178-2185, 2008.
53. O'Day S, Gonzalez R, Lawson D, et al: Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma (abstract 8528). J Clin Oncol 25(18S):479s, 2007.
54. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008.
55. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703, 2008. (Pubitemid 351860862)
56. Richards JM, Bedikian AY, Gonzalez R, et al: High-dose Allovectin-7® in patients with advanced metastatic melanoma: Final phase 2 data and design of phase 3 registration trial (abstract 7543). J Clin Oncol 23(16S):720s, 2005.